Pharmaceutical

Stephen Dilly Receives the 2023 Bloom Burton Award

Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Stephen Dilly,…

1 year ago

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Positive Conclusion Reached in Immunomodulator I Patent OppositionPatent opposition hearing cancelledLONDON, UK / ACCESSWIRE / September 29, 2023 / Poolbeg…

1 year ago

Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

VANCOUVER, BC / ACCESSWIRE / September 28, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to…

1 year ago

Medexus and medac Agree to Amend US Treosulfan Agreement

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to…

1 year ago

Rancho Biosciences Will Be Exhibiting at the Festival of Genomics & Biodata 2023

SAN DIEGO, CA / ACCESSWIRE / September 28, 2023 / Rancho Biosciences, the leading Data Science Service company, will be…

1 year ago

“The Future Is Bright” With Opportunities to Grow: BioAlberta’s State of the Industry Reports on Alberta’s Life Sciences and Healthcare Industry

EDMONTON, Alberta--(BUSINESS WIRE)--BioAlberta has published its 2023 State of the Industry (SOI) report. This year’s report includes new insights and…

1 year ago

Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023

INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase…

1 year ago

Nusano to Participate in October Investor Conferences

NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced…

1 year ago

Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered…

1 year ago